Applied DNA Sciences, Inc.

387 articles about Applied DNA Sciences, Inc.

• Applied DNA First Quarter Fiscal 2022 Financial Results Feature Record Quarterly Revenues

  2/10/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the first quarter of fiscal 2022, ended December 31, 2021.

• Applied DNA Schedules Fiscal 2022 First Quarter Financial Results Conference Call and Webcast for Thursday, February 10, 2022

  2/3/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial results after market close on Thursday, February 10, 2022.

• Applied DNA to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

  1/28/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), intends to deploy its Linea™ 1.0 COVID-19 Assay (the “Linea 1.0 Assay” or the “Assay”), part of ADCL’s Linea COVID-19 diagnostics and testing portfolio, for the rapid detection of samples containing a mutation profile that is indicative of the BA.2 subvariant (BA.2) of Omicron in COVID-19-positive samples.

• Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit

  1/21/2022

  Applied DNA Sciences, Inc. announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit.

• Applied DNA Announces Continued Momentum in COVID-19 Testing Demand

  1/18/2022

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, has seen COVID-19 testing levels increase greater than 90% for the quarter ended December 31, 2021, compared to the fiscal quarter ended September 30, 2021.

• Applied DNA Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test

  1/4/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has received conditional approval from the New York State Department of Health (NYSDOH) for its Linea™ 2.0 Assay (the “Linea 2.0 Assay”) as a Laboratory Developed Test (LDT), pending a final review of the assay’s validation data by NYSDOH.

• Applied DNA and Stratum Reservoir (Isotech) Sign Memorandum of Understanding to Leverage Isotopic Analysis for Enhanced DNA-Based Cotton Authenticity and Provenance

  12/15/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), and Stratum Reservoir (Isotech), LLC (“Isotech”), today announced that they have entered into a Memorandum of Understanding (MoU).

• Applied DNA Reports Fourth Quarter and Full Fiscal Year 2021 Financial Results, Continuing Momentum in Diagnostic Testing

  12/9/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2021.

• Applied DNA Advances Cotton Genomics-based Methodology for Determination of Authenticity and Provenance

  12/6/2021

  Applied DNA Sciences, Inc. announced today a development in its cotton genomics program (the “Program”) that the Company believes can bring forensic proof of cotton authenticity and provenance specifically related to regional cotton varietals to give brands and relevant regulatory authorities access to fiber origin data regardless of location of manufacture.

• Applied DNA Schedules Fourth Quarter and Full Fiscal Year 2021 Financial Results Conference Call and Webcast for Thursday, December 9, 2021

  12/3/2021

  Applied DNA Sciences, Inc. today announced that it will report its fourth quarter and full fiscal year 2021 financial results after market close on Thursday, December 9, 2021.

• Applied DNA Announces Strategy to Address Omicron SARS-CoV-2 Variant, Introduces Linea™ 2.0 COVID-19 Assay Kit

  11/29/2021

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, announced its COVID-19 diagnostic strategy in response to the emergence of Omicron, a newly identified SARS-CoV-2 variant of concern.

• Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

  11/15/2021

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, and its majority-owned subsidiary LineaRx, Inc., a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, announced the receipt of repeat orders from diagnostic customers and a first Contract Research Organization order from a new biotherapeutic customer, a federally funded research and development laboratory focused on cancer research.

• Research Publication Demonstrates Utility of Applied DNA’s LinearDNA™ in Non-Viral CAR T Manufacturing Systems

  11/9/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”),announced the publication of a study in Molecular Therapy: Methods and Clinical Development on a methodology for the manufacture of novel types of CAR constructs that employ the Company’s LinearDNA™ as part of a manufacturing process for the efficient generation of CD19-specific CAR T-cells (CAR19 T-cells) based on co-electroporation of a LinearDNA transposon and mRNA encoding of piggyBac transposase.

• Applied DNA and CLEARED4 Offer Fast, Cost-Effective and Turnkey Integrated Solution for Compliance with OSHA Mandate for COVID-19 Vaccination and Testing

  11/5/2021

  Applied DNA Sciences, Inc. stand ready to help large employers prepare for compliance with the federally directed OSHA Emergency Temporary Standard (“ETS”) with a turnkey and cost-effective integrated offering to efficiently track employee COVID-19 vaccination status

• Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ SARS-CoV-2 Mutation Panel

  10/25/2021

  Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea ™ SARS-CoV-2 Mutation Panel

• Applied DNA Implements safeCircle™ COVID-19 Testing Program at Sarah Lawrence College

  10/12/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), announced that safeCircle™, its high-throughput, pooled COVID-19 testing program, has been implemented at Sarah Lawrence College (the “College”) as an addition to the College’s in-house testing practice to monitor for the prevalence of COVID-19 during the College’s Fall 2021 semester.

• Applied DNA Announces CertainT® Platform Support for TruTrace StrainSecure™ 2.0 for Next Generation Cannabis Tagging, Testing and Tracking

  9/14/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that its CertainT® platform has added support for StrainSecure 2.0 by TruTrace Technologies, Inc.

• Applied DNA to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Applied DNA to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

• Applied DNA Announces Third Quarter Fiscal 2021

  8/12/2021

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, announced consolidated financial results for the three and nine months ended June 30, 2021.

• Applied DNA Schedules Fiscal 2021 Third Quarter Financial Results Conference Call and Webcast for Thursday, August 12, 2021

  8/5/2021

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction - based DNA manufacturing and nucleic acid-based technologies, announced that it will report fiscal 2021 third quarter financial results after market close on Thursday, August 12, 2021.